Continuous and intermittent dosing of lonafarnib potentiates the therapeutic efficacy of docetaxel on preclinical human prostate cancer models.

Full Abstract

Lonafarnib is a potent, selective farnesyltransferase inhibitor (FTI) undergoing clinical studies for the treatment of solid tumors and hematological malignancies. Preclinically, a number of FTIs, including lonafarnib, interact with taxanes to inhibit cancer cell growth in an additive/synergistic manner. These observations provided rationale for investigating the effects of combining lonafarnib and docetaxel on preclinical prostate cancer models. To date, docetaxel is the only chemotherapeutic agent in clinical use for hormone-refractory prostate cancer. In vitro experiments with 22Rv1, LNCaP, DU-145, PC3 and PC3-M prostate cancer cell lines showed significantly enhanced inhibition of cell proliferation and apoptosis when lonafarnib was added to docetaxel. In human tumor xenograft models, continuous coadministration of lonafarnib with docetaxel caused marked tumor regressions (24-47%) in tumors from all of the cell types as well as parental CWR22 xenografts. Intermittent dosing of lonafarnib (5 days on then 5 days off) coadministered with docetaxel produced similar regressions in hormone-refractory 22Rv1 tumors. 22Rv1 tumors progressing on docetaxel treatment also responded to treatment with intermittent lonafarnib (5 days on then 5 days off). Moreover, animals did not exhibit any signs of toxicity during coadministration of lonafarnib and docetaxel. In conclusion, coadministration of continuous and intermittent lonafarnib enhanced the antitumor activity of docetaxel in a panel of prostate cancer models. An intermittent dosing schedule of lonafarnib coadministered with docetaxel may allow enhanced efficacy to that of continuous dosing by improving the tolerability of higher doses of lonafarnib.

Author information

Author/s: Liu, Gongjie (G); Taylor, Stacey A (SA); Marrinan, Cindy H (CH); Hsieh, Yunsheng (Y); Bishop, W Robert (WR); Kirschmeier, Paul (P); Long, Brian J (BJ);

Affiliation: Schering-Plough Research Institute, Biological Research - Oncology, Kenilworth, NJ 07033, USA.

Journal and publication information

Publication Type: Journal Article

Journal: International journal of cancer. Journal international du cancer (Int J Cancer), published in United States. (Language: eng)

Reference: 2009-Dec; vol 125 (issue 11) : pp 2711-20

Dates: Created 2009/10/05; Completed 2009/11/06;

PMID: 19530253, status: MEDLINE (last retrieval date: 11/6/2009, IMS Date: )

Sourced from the National Library of Medicine. Abstract text and other information may be subject to copyright.

External Links for this article
(including full text providers, if available):

Click Electronic Full-text Provider Links to see options for finding the electronic full text links to this article. Note there may be a subscription or fee required for access to the full text. See our FAQ for information on finding FREE full text articles.

This article may also be located in paper journal collections available in many libraries. Use the Journal and Publication Information above to find the full article.

MeSH headings (categories)

This article was linked to the MESH Headings shown below.

Male
Mice
Mice, Nude
Mice, SCID
Neoplasms, Hormone-Dependent - blood; drug therapy; pathology
Piperidines - blood; pharmacokinetics; therapeutic use
Prostatic Neoplasms - blood; drug therapy; pathology
Pyridines - blood; pharmacokinetics; therapeutic use
Taxoids - therapeutic use
Xenograft Model Antitumor Assays

Associated Chemicals: Antineoplastic Agents (0) ; Piperidines (0) ; Pyridines (0) ; Taxoids (0) ; docetaxel (114977-28-5) ; lonafarnib (193275-84-2)

These are the highest related articles currently in the database: